Abstract

The pharmacological profile of benzodiazepines includes respiratory depression, and theoretically benzodiazepines might contribute to respiratory dysfunction. There are currently no data that indicate that benzodiazepines are problematic in COVID-19, and the risk is expected to be limited. Benzodiazepines are effective and frequently used, and if there is a clear indication in patients with COVID-19 there is insufficient reason to avoid benzodiazepines based on respiratory depression as side effect.